Patient Characteristics
| . | All (N = 41) . | IR+ (N = 20) . | IR− (N = 21) . |
|---|---|---|---|
| Age at end of last chemotherapy | |||
| Mean (median) | 45 (45) yr | 43 (42) yr | 48 (47) yr |
| Range | 23 to 74 yr | 23 to 70 yr | 32 to 74 yr |
| Gender | 18 M, 23 F | 8 M, 12 F | 10 M, 11 F |
| Histology | |||
| FSC | 27 | 12 | 15 |
| FM | 13 | 7 | 6 |
| DSC | 1 | 1 | |
| Stage | |||
| II | 1 | 1 | |
| III | 10 | 5 | 5 |
| IV | 30 | 14 | 16 |
| Tumor isotypes | |||
| IgM κ | 16 | 8 | 8 |
| IgM λ | 15 | 8 | 7 |
| IgG κ | 4 | 2 | 2 |
| IgG λ | 5 | 1 | 4 |
| IgA λ | 1 | 1 | |
| Treatment | |||
| First remission | 32 | 14 | 18 |
| Subsequent remission | 9 | 6 | 3 Time from Dx to end of last chemotx |
| Mean (median) | 2.6 (1.2) yr | 3.0 (0.9) yr | 2.3 (1.7) yr Time from end of last chemotx to vaccine |
| Mean (median) | 8.4 (6) mo | 9.6 (7) mo | 7.2 (5) mo |
| Cycles of chemotx | |||
| ≤8 | 17 | 7 | 10 |
| >8 | 24 | 13 | 11 |
| Disease status | |||
| Before Tx: | |||
| Clinical remission | 21 | 15 | 6 |
| Residual disease | 20 | 5 | 15 |
| . | All (N = 41) . | IR+ (N = 20) . | IR− (N = 21) . |
|---|---|---|---|
| Age at end of last chemotherapy | |||
| Mean (median) | 45 (45) yr | 43 (42) yr | 48 (47) yr |
| Range | 23 to 74 yr | 23 to 70 yr | 32 to 74 yr |
| Gender | 18 M, 23 F | 8 M, 12 F | 10 M, 11 F |
| Histology | |||
| FSC | 27 | 12 | 15 |
| FM | 13 | 7 | 6 |
| DSC | 1 | 1 | |
| Stage | |||
| II | 1 | 1 | |
| III | 10 | 5 | 5 |
| IV | 30 | 14 | 16 |
| Tumor isotypes | |||
| IgM κ | 16 | 8 | 8 |
| IgM λ | 15 | 8 | 7 |
| IgG κ | 4 | 2 | 2 |
| IgG λ | 5 | 1 | 4 |
| IgA λ | 1 | 1 | |
| Treatment | |||
| First remission | 32 | 14 | 18 |
| Subsequent remission | 9 | 6 | 3 Time from Dx to end of last chemotx |
| Mean (median) | 2.6 (1.2) yr | 3.0 (0.9) yr | 2.3 (1.7) yr Time from end of last chemotx to vaccine |
| Mean (median) | 8.4 (6) mo | 9.6 (7) mo | 7.2 (5) mo |
| Cycles of chemotx | |||
| ≤8 | 17 | 7 | 10 |
| >8 | 24 | 13 | 11 |
| Disease status | |||
| Before Tx: | |||
| Clinical remission | 21 | 15 | 6 |
| Residual disease | 20 | 5 | 15 |
Abbreviation: DSC, diffuse small cleaved cell lymphoma.